Veeva SiteVault Free allows sites to share and collaborate remotely with study monitors
for source document review and verification
Veeva supporting industrywide drive to accelerate study execution
and improve trial quality across sites, sponsors, and CROs
PLEASANTON, CA — April 2, 2020 – Veeva Systems (NYSE:VEEV) today announced new remote monitoring capabilities in Veeva SiteVault Free for source document review and verification in clinical trials. Veeva SiteVault Free gives research sites a free eRegulatory application to efficiently manage study documentation and now with remote monitoring, allows study monitors to access, review, and collaborate on content online. Sites can centralize monitoring and communication with sponsors and CROs using a free system that is compliant with 21 CFR Part 11 and HIPAA requirements.
“Remote monitoring supports the immediate need for sites and study monitors to continue working together while onsite visits have largely stopped,” said Bree Burks, RN, MSN, vice president of site strategy at Veeva and a former clinical research director. “Veeva SiteVault Free gives sites access to remote monitoring capabilities, at no cost, so they can keep running studies and treating patients.”
SiteVault Free allows sites, sponsors, and CROs to remotely manage and track the workflow and downstream processes for source document review and verification. Sites and study monitors can easily view, comment, and respond to questions in a single, centralized system. Reporting, dashboards, and automatic notifications enable stakeholders to organize their tasks, get complete visibility into documents, and prioritize activities for immediate action.
Remote monitoring is available today in Veeva SiteVault Free. See a demo and learn more at sites.veeva.com/RemoteMonitoring.
What Sites are Saying About Remote Monitoring in Veeva SiteVault Free
“I’m excited by what Veeva is doing to help the industry,” said Trisha Locke, chief executive officer at Keystone Research. “As a high-volume ophthalmology site, we needed a solution that allows sponsors to access our study data. Veeva SiteVault Free gives us a free, compliant solution to manage regulatory documents and provide remote access to source information.”
“COVID-19 has impacted our ability to see patients and monitors onsite,” said William Chrvala, CCRC, managing director of Mid Hudson Medical Research, PLLC. “Veeva SiteVault Free helps us quickly respond to changing business practices and focus on what matters most – our study participants.”
“The ability to monitor studies remotely improves data quality and real-time responsiveness,” said Amanda Wright, vice president of partnership development at Javara. “Solutions like Veeva SiteVault Free can help sites improve engagement with sponsors and CROs.”
About Veeva SiteVault
Veeva SiteVault reduces the administrative burden of managing regulatory documents and processes for all trials with capabilities such as remote monitoring, electronic signatures, certified copy workflows, and reporting. Available in two editions, SiteVault Free comes with full training and support, and SiteVault Enterprise provides customized reports, tailored workflows, and open APIs for integrations. For more information about Veeva SiteVault or to sign-up for SiteVault Free, visit sites.veeva.com.
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 850 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-K for the period ended January 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.